Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre retrospective study

Figures & data

Figure 1. Study design.

Table I. Characteristics of patients in Group 1.

	Radical intervention + HIPEC (n = 19)	Radical intervention (n = 19)
Man	15 (79%)	13 (68%)
Woman	4 (21%)	6 (32%)
Primary localisation:
Antral part	4 (21%)	7 (37%)
Corpus	9 (47%)	5 (26%)
Antral part + corpus	–	1 (5%)
Subtotal	6 (32%)	6 (32%)
Primary histological grade:
G2	2 (11%)	1 (5%)
G3	9 (47%)	6 (32%)
G4	7 (37%)	10 (52%)
Signet ring cell	1 (5%)	2 (11%)
Primary tumour stage (TNM 7)
pT4a	15 (79%)	18 (95%)
pT4b	4 (21%)	1 (5%)
Area of serosa’s infiltration
Less than 20 cm^2	7 (36%)	7 (36%)
More than 20 cm^2	6 (32%)	6 (32%)
Subtotal infiltration	6 (32%)	6 (32%)
Stage (TNM 7)
IIB	8 (43%)	11 (58%)
IIIA	1 (5%)	2 (10%)
IIIB	5 (26%)	3 (16%)
IIIC	5 (26%)	3 (16%)
Lymphodissection
D1	8 (42%)	10 (52%)
D2 (D1+)	11 (58%)	9 (48%)

Table II. Characteristics of patients in Group 2.

	Cytoreductive intervention + HIPEC  + chemo (n = 20)	Palliative chemo (n = 20)
Man	10 (50%)	16 (80%)
Woman	10 (50%)	4 (20%)
Primary localisation:
Antral part	2 (10%)	7 (35%)
Corpus	5 (25%)	4 (20%)
Antral part + corpus	6 (30%)	5 (25%)
Subtotal	7 (35%)	4 (20%)
Primary histological grade:
G2	1 (5%)	1 (5%)
G3	2 (10%)	10 (50%)
G4	14 (70%)	6 (30%)
Signet ring cell	2 (10%)	3 (15%)
Mucinosus	1 (5%)	–
Stage of dissemination (JGCA):
Р0 (CY1)	2 (10%)	2 (10%)
Р1	10 (50%)	11 (55%)
Р2	7 (35%)	6 (30%)
Р3	1 (5%)	1 (5%)
Mean PCI	3.4 (0–14)	4.2 (0–18)
Lymphodissection
D1	14 (70%)	–
D2 (D1+)	6 (30%)	–

Figure 2. Cumulative censored overall survival in gastric cancer patients with a high risk of intraperitoneal disease progression after the HIPEC procedure in adjuvant regime and in the surgical control subgroup.

Figure 3. Cumulative censored overall survival in gastric cancer patients with peritoneal dissemination after combined therapy with HIPEC and in the control subgroup.

Figure 4. Cumulative censored overall survival in gastric cancer patients with diffuse peritoneal carcinomatosis with symptomatic ascites after use of HIPEC and after best supportive care.